Scorpio1113
:
hi i dont have the subscription but i’m really curious about the content, do you mind to more or less brief me a bit about the article? Thanks in advance!
Northsea9
:
The current issue in the weight loss market is that the side effects of weight loss drugs are being masked. Current weight loss drugs not only focus on weight loss but also aim to minimize side effects. This is the core of weight loss drug development! The functions and research technologies of weight loss are very mature! However, reducing side effects is the only standard to measure value! The sharp increase in complications and chronic diseases caused by current weight loss drugs is the reason for the cooling market. This is because there may be potential legal disputes in the future related to pharmaceuticals.
Scorpio1113 : hi i dont have the subscription but i’m really curious about the content, do you mind to more or less brief me a bit about the article? Thanks in advance!
102875548 OP Scorpio1113 : It is not as if novo nordisk have the market cornered as earlier thought, i have bought novo earlier.
IMHO, i think the market is reacting ahead, the obesity market is large enough for all. Viking is a late comer, i also put some bets there.
Scorpio1113 102875548 OP : Thanks a lot bro, have a nice day!
Northsea9 : The current issue in the weight loss market is that the side effects of weight loss drugs are being masked. Current weight loss drugs not only focus on weight loss but also aim to minimize side effects. This is the core of weight loss drug development! The functions and research technologies of weight loss are very mature! However, reducing side effects is the only standard to measure value! The sharp increase in complications and chronic diseases caused by current weight loss drugs is the reason for the cooling market. This is because there may be potential legal disputes in the future related to pharmaceuticals.